HeartBeam Wins FDA Total Product Life Cycle Advisory Program Pilot Acceptance For Heart Attack Assessment Technology
Acceptance into FDA’s TAP Pilot follows Breakthrough Device Designation granted earlier this month for HeartBeam’s heart attack assessment technologyTAP Pilot provides dedicated FDA advisors and early engagement with
HeartBeam's heart attack technology got special help from the FDA. This means the government is working closely with them early on.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.